We are greatly interested in the article by Sircar et al,1 which demonstrates the efficacy of febuxostat in retarding estimated glomerular filtration rate decline in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia. Numerous studies have demonstrated a relationship between serum uric acid levels and cardiovascular morbid entities, including kidney diseases.2 Others have explored the effectiveness of conventional hypouricemic agents such as allopurinol in slowing CKD progression.